FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
334PDF: 91 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
582PDF: 0 -
Whole exome sequencing in a family with thromboangiitis obliterans
19PDF: 5SUPPLEMENTARY FILES: 3 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
332PDF: 83 -
PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany
284PDF: 82 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
340PDF: 77 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
307PDF: 70 -
CO17 | Clinical relevance of isolated anti-phosphatidylserine/ prothrombin antibody positivity A. Hoxha1, P. Žigon2,3, L. Katja2,3, S. Čučnik2,4, Ž. Rotar2,5, S. Gavasso1, P. Zerbinati1, G. Gobbo1, P. Simioni1 | 1University of Padua, Internal Medicine Unit, Thrombotic and Hemorrhagic Centre, Department of Medicine-DIMED, Padua, Italy; 2University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia; 3University of Primorska, Faculty of Mathematics, Natural Sciences and Information Technologies, Koper, Slovenia; 4University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia; 5University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
591PDF: 0 -
PO48 | Thrombotic risk evaluation and thrombophilia testing in β-thalassemia patients: a retrospective cohort analysis from a reference regional center G.M. Camarda1,2*, S. Raso1*, R. Di Maggio1, M. Vinciguerra3, A. Giangreco1, A. Inzerillo1, A. Maggio, M. Napolitano1,2 | *These authors contributed equally to this abstract; 1Hematology and Rare Diseases Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo; 2Division of Hematology Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “ProMISE”, Palermo; 3UOSD Molecular Diagnosis of Rare Blood Diseases, Azienda Ospedaliera, Ospedali Riuniti Villa Sofia, Cervello, Palermo, Italy
604PDF: 0
